Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks - Concepedia

Concepedia

Publication | Open Access

Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks

DOI Full Paper Access

12

Citations

36

References

2023

Year

Scott Fung, Calvin Q. Pan, Grace Lai–Hung Wong, Wai‐Kay Seto, Sang Hoon Ahn, Chi‐Yi Chen, Hie‐Won Hann, Maciej Jabłkowski, Yoon Jun Kim, Cihan Yurdaydın,

Alimentary Pharmacology & Therapeutics

Abstract

Despite on-treatment differences in lipid profiles with TAF and TDF, predicted cardiovascular risk and clinical events were similar for both groups after 96 weeks.

References

	Year	Citations

Page 1